Search for a trial

A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third generation EGFR TKI

This study has been transitioned to CTIS with ID 2024-512288-29-00 check the CTIS register for the current data. The aim of this prospective single-arm phase II study is to evaluate the efficacy of amivantamab and bevacizumab added to continued…

Assessing long-term outcomes of dupixent treatment in patients with chronic rhinosinusitis with nasal polyposis

As part of your treatment, you will receive DUPIXENT. We would like to learn what the experiences of patients are with this medical product and if you notice any changes. The aim of the study is to better understand the characteristics of patients…

A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor

This study has been transitioned to CTIS with ID 2024-513770-22-00 check the CTIS register for the current data. Primary objective:• Evaluate the anti-tumor activity of GEN1046 as monotherapy and in combination with pembrolizumab in subjects with…

A multicentre single-arm phase II trial assessing the safety and efficacy of
first-line osimertinib and locally ablative radiotherapy in patients with
synchronous oligo-metastatic EGFR-mutant non-small cell lung cancer

The objective of this trial is to evaluate safety (in terms of grade >=2 pneumonitis, requiringmedical treatment) and efficacy (in terms of PFS) in patients with synchronous oligometastatic EGFR-mutant NSCLC treated with osimertinib and…